Butatron (Phenylbutazone Tablets) 1 gm (1 Tablet) | On Sale | EntirelyPets Rx
Licensed U.S. Pet Pharmacy | Verified Pharmacy
Mobile Menu
Search Submit
Live Chat My Account
View Cart 0

Sitewide Sale! Plus FREE SHIPPING on ground orders over $49!  15% OFF!  Use Code EPX15 *

  • Product ImageProduct Image

Butatron (Phenylbutazone Tablets) 1 gm (1 Tablet)

Item# 1BUT001S
FREE SHIPPING Over $79! * Pet Food & Other Exclusions
1. Select tablet:

Price too low to show

Add to cart to see low price
  1. We'll ask for your vet's info during check out.
  2. We'll verify your prescription and ship your order! Learn more >>
Recurring Saings in EprxAUTOSHIP & SAVE[Details]
Recurring Saings in EprxAUTOSHIP & SAVE[Details]
$22.95Reg $29.99
$0.77Reg $0.87
  • Description
  • Directions
  • Reviews


Phenylbutazone, commonly known as Bute, is a non-steroidal anti-inflammatory drug that is used for musculo-skeletal analgesia (pain relief) and also has anti-pyretic (fever reduction) properties. It can be used for a wide range of problems such as muscle soreness and trauma, tendon and ligament sprain/strains, joint pain and arthritis. It also may be used to reduce pain and inflammation during an active infection and after surgery.

Key Benefits

  • Rapid onset of activity: usually provides relief within 24 hours
  • Proven: safe and effective
  • Versatile: treats inflammatory conditions in both dogs and horses
  • Safe: approved by FDA

How It Works

Phenylbutazone is a non-steroidal anti-inflammatory drug (NSAID) which through its anti-inflammatory action can relieve pain, reduce inflammation and reduce fever.


tablets are indicated for the management of musculoskeletal conditions such as osteoarthritis, particularly where continued mobility is considered desirable.

Phenylbutazone possesses non-hormonal, anti-inflammatory activity of value in the management of musculoskeletal conditions in dogs and horses such as the arthritides, including osteoarthritis, and as an aid in the relief of inflammation associated with intervertebral disc syndrome in dogs.


View Butatron Drug Facts Sheet.

Dosage: Dogs:

Orally 20 mg per pound body weight (100 mg/5 lbs.) daily in 3 divided doses, not to exceed 800 mg daily regardless of body weight.

Dosage: Horses:

Orally 1-2 grams per 500 lbs. body weight, not to exceed 4 grams daily.


  1. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing the desired clinical response.
  2. In many cases tablets may be crushed and given with feed. Reduce the dosage as symptoms regress. In some cases treatment may be given only when symptoms appear with no need for continuous medication.
  3. In animals, phenylbutazone is largely metabolized in 8 hours. It is recommended that a third of the daily dose be administered at 8 hour intervals.
  4. Many chronic conditions will respond to phenylbutazone therapy but discontinuance of treatment may result in the recurrence of symptoms.


Federal law restricts this drug to use by or on the order of a licensed veterinarian.


Phenylbutazone should not be administered to animals with serious hepatic, renal or cardiac pathology, or those with a history of blood dyscrasia.


Phenylbutazone should not be administered to meat, egg or milk producing animals because the status of residues of drug remaining in edible tissues has not been determined.

Hazards & Precautions:

  1. Use with caution in animals with a history of drug allergy.
  2. Stop medication at the first sign of gastrointestinal upset, jaundice or blood dyscrasia. Authenticated cases of agranulocytosis associated with phenylbutazone have occurred in man. Phenylbutazone induced blood dyscrasias have been reported in dogs. Thrombocylopenia and leukopenia are early manifestations followed by nonregenerative anemia. The occurrence of this reaction is not dose dependent and is unpredictable. To guard against this possibility, conduct routine blood counts at not more than 7 day intervals during the early course of therapy and at intervals of not more than 14 days throughout the course of therapy. Any significant fall in the total white count, relative decrease in granulocytes or black or tarry stools should be regarded as a signal for immediate cessation of therapy and institution of appropriate treatment.
  3. When treating inflammatory conditions associated with infection, specific anti-infective therapy is required.
  4. Response to phenylbutazone therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days of therapy, re-evaluate diagnosis and therapeutic regimen.


Store at controlled room temperature, 20°C-25°C (68°F-77°F).

Customers Who Bought Also Bought